Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

CXD101 is a histone deacetylase 1 (HDAC1), HDAC2, and HDAC3 inhibitor (IC50s = 63, 570, and 550 nM, respectively).1 It increases acetylation of lysine 9 on histone H3 (H3K9Ac) in Colon-26 colon cancer cells when used at a concentration of 2.7 µM.2 CXD101 (50 mg/kg per day) decreases tumor volume, reduces tumor levels of macrophages, and increases tumor levels of Cd4+ and Cd8+ T cells without affecting body weight in a Colon-26 murine colon cancer model. It increases serum levels of IgG and IgM antibodies thirty days after administration in mice immunized with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein.3
WARNING This product is not for human or veterinary use.
1. A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. Cancer 125(1), 99-108 (2019).
2. Immune modulation underpins the anti-
3. The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity. Commun. Biol. 6(1), 102 (2023).